Page 677 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 30 Tumors of the Urinary System 655

52. Nieset JR, Harmon JF, Johnson TE, et al.: Comparison of adaptive 71. Thompson MF, Litster AL, Platell JL, et al.: Canine bacterial uri-
radiotherapy techniques for external radiation therapy of canine nary tract infections: new developments in old pathogens, Vet J
bladder cancer, Vet Radiol Ultrasound 55:644–650, 2014. 190:22–27, 2011.
VetBooks.ir 53. Nieset JR, Harmon JF, Larue SM: Use of cone-beam computed 72. Budreckis DM, Byrne BA, Pollard RE, et al.: Bacterial urinary tract
tomography to characterize daily urinary bladder variations dur-
infections associated with transitional cell carcinoma in dogs, J Vet
Intern Med 29:828–833, 2015.
ing fractionated radiotherapy for canine bladder cancer, Vet Radiol
Ultrasound 52:580–588, 2011. 73. Iida N, Dzutsev A, Stewart CA, et al.: Commensal bacteria control
54. McMillan SK, Boria P, Moore GE, et al.: Antitumor effects of dera- cancer response to therapy by modulating the tumor microenviron-
coxib treatment in 26 dogs with transitional cell carcinoma of the ment, Science 342:967–970, 2013.
urinary bladder, J Am Vet Med Assoc 239:1084–1089, 2011. 74. Ohnishi S, Ma N, Thanan R, et al.: DNA damage in inflammation-
55. Robat C, Burton J, Thamm D, et al.: Retrospective evaluation of related carcinogenesis and cancer stem cells, Oxid Med Cell Longev
doxorubicin-piroxicam combination for the treatment of transi- 2013387014, 2013.
tional cell carcinoma in dogs, J Small Anim Pract 54:67–74, 2013. 75. Chung S-D, Tsai M-C, Lin C-C, et al.: A case-control study on
56. Allstadt SD, Rodriguez Jr CO, Boostrom B, et al.: Randomized the association between bladder cancer and prior bladder calculus,
phase III trial of piroxicam in combination with mitoxantrone or BMC Cancer 13:117, 2013.
carboplatin for first-line treatment of urogenital tract transitional 76. Hall JL, Holmes MA, Baines SJ: Prevalence and antimicrobial resis-
cell carcinoma in dogs, J Vet Intern Med 29:261–267, 2015. tance of canine urinary tract pathogens, Vet Rec 173:549, 2013.
57. Marconato L, Zini E, Lindner D, et al.: Toxic effects and antitumor 77. Boothe D, Smaha T, Carpenter DM, et al.: Antimicrobial resis-
response of gemcitabine in combination with piroxicam treatment tance and pharmacodynamics of canine and feline pathogenic E.
in dogs with transitional cell carcinoma of the urinary bladder, coli in the United States, J Am Anim Hosp Assoc 48:379–389, 2012.
J Am Vet Med Assoc 238:1004–1010, 2011. 78. Wagner S, Gally DL, Argyle SA: Multidrug-resistant Escherichia
58. Arnold EJ, Childress MO, Fourez LM, et al.: Clinical trial of vin- coli from canine urinary tract infections tend to have commensal
blastine in dogs with transitional cell carcinoma of the urinary phylotypes, lower prevalence of virulence determinants and ampC-
bladder, J Vet Intern Med 25:1385–1390, 2011. replicons, Vet Microbiol 169:171–178, 2014.
59. Knapp DW, Ruple-Czerniak A, Ramos-Vara JA, et al.: A nonselec- 79. Nam E-H, Ko S, Chae J-S, et al.: Characterization and zoonotic
tive cyclooxygenase inhibitor enhances the activity of vinblastine potential of uropathogenic Escherichia coli isolated from dogs,
in a naturally-occurring canine model of invasive urothelial carci- J Microbiol Biotechnol 23:422–429, 2013.
noma, Bladder Cancer 2:241–250, 2016. 80. Wong C, Epstein SE, Westropp JL: Antimicrobial susceptibil-
60. Henry CJ, Flesner BK, Bechtel SA, et al.: Clinical evaluation of ity patterns in urinary tract infections in dogs (2010-2013), J Vet
tavocept to decrease diuresis time and volume in dogs with blad- Intern Med 29:1045–1052, 2015.
der cancer receiving cisplatin, J Vet Intern Med, 2017. https://doi. 81. Lee BSB, Bhuta T, Simpson JM, et al.: Methenamine hippurate
org/10.1111/jvim.14848. Epub ahead of print. for preventing urinary tract infections, Cochrane database Syst Rev
61. Schrempp DR, Childress MO, Stewart JC, et al.: Metronomic 10:CD003265, 2012.
administration of chlorambucil for treatment of dogs with urinary 82. Tariq R, Pardi DS, Tosh PK, et al.: Fecal microbiota transplantation
bladder transitional cell carcinoma, J Am Vet Med Assoc 242:1534– for recurrent clostridium difficile infection reduces recurrent urinary
1538, 2013. tract infection frequency, Clin Infect Dis 65:1745–1747, 2017.
62. Knapp DW, Henry CJ, Widmer WR, et al.: Randomized trial of 83. Schwarz PD, Greene RW, Patnaik AK: Urinary bladder tumors in
cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with the cat: a review of 27 cases, J Am Anim Hosp Assoc 21:237–245,
transitional cell carcinoma of the urinary bladder, J Vet Intern Med 1985.
27:126–133, 2013. 84. Wilson HM, Chun R, Larson VS, et al.: Clinical signs, treatments,
63. Leach TN, Childress MO, Greene SN, et al.: Prospective trial of and outcome in cats with transitional cell carcinoma of the urinary
metronomic chlorambucil chemotherapy in dogs with naturally bladder: 20 cases (1990-2004), J Am Vet Med Assoc 231:101–106,
occurring cancer, Vet Comp Oncol 10:102–120, 2012. 2007.
64. Custead MR, Weng HY, Childress MO: Retrospective compari- 85. Sapierzyński R, Malicka E, Bielecki W, et al.: Tumors of the uro-
son of three doses of metronomic chlorambucil for tolerability and genital system in dogs and cats. retrospective review of 138 cases,
efficacy in dogs with spontaneous cancer, Vet Comp Oncol 15:808– Pol J Vet Sci 10:97–103, 2007.
819, 2017. 86. Geigy CA, Dandrieux J, Miclard J, et al.: Extranodal B-cell lym-
65. Eichstadt LR, Moore GE, Childress MO: Risk factors for treat- phoma in the urinary bladder with cytological evidence of concur-
ment-related adverse events in cancer-bearing dogs receiving rent involvement of the gall bladder in a cat, J Small Anim Pract
piroxicam, Vet Comp Oncol 15:1346–1353, 2017. 51:280–287, 2010.
66. Dhawan D, Ramos-Vara JA, Naughton JF, et al.: Targeting folate 87. Pavia PR, Havig ME, Donovan TA, et al.: Malignant peripheral
receptors to treat invasive urinary bladder cancer, Cancer Res nerve sheath tumour of the urinary bladder in a cat, J Small Anim
73:875–884, 2013. Pract 53:245–248, 2012.
67. Hahn NM, Bonney PL, Dhawan D, et al.: Subcutaneous 5-azaciti- 88. Khodakaram-Tafti A, Shirian S, Vesal N, et al.: Lipoma of the uri-
dine treatment of naturally occurring canine urothelial carcinoma: nary bladder in a cat, J Comp Pathol 144:212–213, 2011.
a novel epigenetic approach to human urothelial carcinoma drug 89. Bommer NX, Hayes AM, Scase TJ, et al.: Clinical features, survival
development, J Urol 187:302–309, 2012. times and COX-1 and COX-2 expression in cats with transitional
68. Fulkerson CM, Dhawan D, Jones DR, et al.: Pharmacokinetics and cell carcinoma of the urinary bladder treated with meloxicam,
toxicity of the novel oral demethylating agent zebularine in labora- J Feline Med Surg 14:527–533, 2012.
tory and tumor bearing dogs, Vet Comp Oncol 15:226–236, 2017. 90. Brace MA, Weisse C, Berent A: Preliminary experience with stent-
69. Abbo AH, Jones DR, Masters AR, et al.: Phase I clinical trial and ing for management of non-urolith urethral obstruction in eight
pharmacokinetics of intravesical mitomycin C in dogs with local- cats, Vet Surg 43:199–208, 2014.
ized transitional cell carcinoma of the urinary bladder, J Vet Intern 91. Christensen NI, Culvenor J, Langova V: Fluoroscopic stent place-
Med 24:1124–1130, 2010. ment for the relief of malignant urethral obstruction in a cat, Aust
70. Lucroy MD, Ridgway TD, Peavy GM, et al.: Preclinical evaluation Vet J 88:478–482, 2010.
of 5-aminolevulinic acid-based photodynamic therapy for canine 92. Newman RG, Mehler SJ, Kitchell BE, et al.: Use of a balloon-
transitional cell carcinoma, Vet Comp Oncol 1:76–85, 2003. expandable metallic stent to relieve malignant urethral obstruction
in a cat, J Am Vet Med Assoc 234:236–239, 2009.